Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study - Summary - MDSpire

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

  • By

  • Matthias Augustin

  • Paul-Gunther Sator

  • Ralph von Kiedrowski

  • Dimitris Rigopoulos

  • Marco Romanelli

  • Pierre-Dominique Ghislain

  • Tiago Torres

  • Dimitrios Ioannides

  • Cynthia Vizcaya

  • Andreas Clemens

  • Weibin Bao

  • Christelle C. Pieterse

  • Barbara Schulz

  • Piotr Jagiello

  • Curdin Conrad

  • April 2, 2026

  • 0 min

Share

Objective:

To assess the long-term retention, effectiveness, and safety of secukinumab in patients with moderate to severe plaque psoriasis in a real-world setting over a 5-year period.

Key Findings:
  • Secukinumab demonstrated high treatment retention and sustained effectiveness over 5 years, with retention rates exceeding 80%.
  • Significant improvements in skin clearance (PASI scores) and quality of life (DLQI scores) were reported by patients.
  • Early intervention with secukinumab is associated with better long-term outcomes, particularly in patients with shorter disease duration.
Interpretation:

Secukinumab is a valuable long-term treatment option for managing moderate to severe plaque psoriasis, significantly improving disease control and patients' quality of life, which is crucial for clinical practice.

Limitations:
  • The study's observational design may introduce bias, potentially affecting the generalizability of the results.
  • Data collection was retrospective for some parameters, which may impact the completeness and accuracy of the findings.
Conclusion:

The SERENA study provides robust real-world evidence supporting the long-term use of secukinumab in moderate to severe plaque psoriasis, highlighting its efficacy and safety, and emphasizing the importance of real-world data in treatment decisions.

Original Source(s)

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

  • by Matthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, Dimitris Rigopoulos, Marco Romanelli, Pierre-Dominique Ghislain, Tiago Torres, Dimitrios Ioannides, Cynthia Vizcaya, Andreas Clemens, Weibin Bao, Christelle C. Pieterse, Barbara Schulz, Piotr Jagiello, Curdin Conrad

  • April 2, 2026

Related Content

Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness